Pharmagenesis, Eli Lilly deal

The companies agreed to isolate and develop antifungal agents derived from microorganisms associated with plants known to be resistant to fungal infections. Pharmagenesis's EcoPharm division will isolate the microorganisms and biological compounds that demonstrate antifungal activity. Lilly is responsible for preclinical and clinical development of lead compounds. ...